イベント

すべて表示

    PEGS Europe 2026: BCG015, A First-in-Class Antibody-Drug Conjugate Targeting TM4SF5 for the Treatment of Hepatocellular Carcinoma

    November 20, 2026
    〜でシェア:

    Abstract

    BCG015 is a first-in-class, fully human ADC targeting TM4SF5 (expressed in ≥70% of HCCs). Discovered via the RenLite® platform, the mAb exhibits high affinity and excellent developability. BCG015 demonstrated superior antitumor efficacy against benchmark ADCs across diverse HCC models. Supported by a highly favorable safety profile in non-human primate toxicology studies, it represents a promising, highly developable therapeutic candidate for liver cancer. 

    The audio is muted. Click to unmute.